-
1 Comment
Yantai Zhenghai Biotechnology Co., Ltd is currently in a long term uptrend where the price is trading 18.0% above its 200 day moving average.
From a valuation standpoint, the stock is 81.7% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 17.5.
Yantai Zhenghai Biotechnology Co., Ltd's total revenue rose by 4.1% to $82M since the same quarter in the previous year.
Its net income has increased by 45.2% to $40M since the same quarter in the previous year.
Finally, its free cash flow grew by 153.6% to $32M since the same quarter in the previous year.
Based on the above factors, Yantai Zhenghai Biotechnology Co., Ltd gets an overall score of 4/5.
| Exchange | SHE |
|---|---|
| CurrencyCode | CNY |
| Sector | Healthcare |
| Industry | Biotechnology |
| ISIN | CNE100002NZ1 |
| Market Cap | 4B |
|---|---|
| PE Ratio | 28.82 |
| Target Price | 26.035 |
| Dividend Yield | 4.1% |
| Beta | 0.37 |
Yantai Zhenghai Biotechnology Co., Ltd. engages in the research and development, production, and marketing of regenerative medical materials in China. The company offers oral repair membranes, absorbable dura mater patches, active biological bones, skin repair membranes, bone repair materials, surgical packing sponges, and self-etching adhesives. It products are used in various fields, such as dentistry, head and neck surgery, neurosurgery, and otolaryngology. Yantai Zhenghai Biotechnology Co., Ltd. was founded in 2003 and is based in Yantai, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 300653.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
